Async + text support · Pharmacy: 503A
Emerge maintains a dedicated resource page for women with endometriosis and PCOS (PMOS). Read Emerge’s endo & PMOS page →
Emerge scores strongly across most of this Charter, and the reason is structural rather than promotional: the published model treats a condition like endometriosis as part of the picture it works around, instead of something to be noted and set aside. Six of seven rows rate strong.
We should be exact about what that does and does not mean, because it matters. Emerge does not treat endometriosis, and nothing here should be read as suggesting it can. What it offers is metabolic care delivered by people who know the rest of your history is there — which is a different and more modest claim.
Here is how Emerge Weight Loss reads against each promise of the Whole-Woman Charter. Each promise is marked none, partial or strong; price is shown but is never part of the rating. GLP-1 medications are not a treatment for endometriosis.
Billing is all-in at $224 a month, with 503A individualised titration, support by text, and — after three months as a patient — a maintenance programme and a medically guided step-down. That last piece is what most providers here do not publish at all, and for a condition managed across decades the phase after weight loss is not a footnote. Support is written rather than video, which is the trade at this price.
Emerge does not publish its pause and cancellation terms in advance, so the one thing you cannot check before enrolling is what leaving involves. Other providers here do publish theirs, and where they do we have said so. We have marked the cost row at partial on that basis — the same standard applied to everyone on this page. Ask for the terms in writing before you commit.
Put these to Emerge Weight Loss in writing, and keep the reply.
Emerge rates near the top because more of what this Charter asks for is actually built here — whole-picture framing, individualised dosing, reachable support, and a plan for after. The unpublished exit terms are a genuine gap and we have scored them as one. Get that answer, then decide.
What is above comes from what this provider chooses to publish, and providers revise their terms without saying so — treat it as a starting point and check it yourself. Havelle is editorial, not clinical: none of this is medical advice, and GLP-1 medications are not a treatment for endometriosis.